StockData

Exozymes Inc. (EXOZ) stock

EXOZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 5/30
$3.43+0.12 (+3.63%)

Close on Nov 18, 2026Market cap $31.84MP/E –Yield –

Exozymes operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Exozymes's operating income for the twelve months ending Sep 30, 2026 was -$11.08M. For fiscal 2025 it was -$9.72M.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$9.72M–
FY2024Dec 31, 2024-$5.93M–
FY2023Dec 31, 2023-$1.80M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$3.05M–
Q2 FY2026Jun 30, 2026-$2.95M–
Q1 FY2026Mar 31, 2026-$2.39M–
Q4 FY2025Dec 31, 2025-$2.70M–
Q3 FY2025Sep 30, 2025-$2.52M–
Q2 FY2025Jun 30, 2025-$2.55M–
Q1 FY2025Mar 31, 2025-$1.95M–
Q4 FY2024Dec 31, 2024-$1.98M–
Q3 FY2024Sep 30, 2024-$1.61M–
Q2 FY2024Jun 30, 2024-$1.33M–
Q1 FY2024Mar 31, 2024-$1.01M–
Q4 FY2023Dec 31, 2023-$985.05K–
Q3 FY2023Sep 30, 2023-$391.85K–

More Exozymes figures

See a number that looks wrong?